Ph3 GDC-9545+ Palbo +/- Letro HER2- BC
(BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER Read Moreabout Ph3 GDC-9545+ Palbo +/- Letro HER2- BC
Phase: III
PH3 Enobosarm AR+ER+HER2- Fulv
(V3002401) ARTEST - A Randomized Crossover Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining ≥40% Who Have Been Previously Treated with a Nonsteroidal Aromatase Inhibitor SERD and CDK 4/6 inhibitor Read Moreabout PH3 Enobosarm AR+ER+HER2- Fulv
Phase: III
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
STAR Ph2 Trila Sacit Gove TNBC
A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213) Read Moreabout STAR Ph2 Trila Sacit Gove TNBC
Phase: II
Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)
A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001) Read Moreabout Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)
Phase: III
Ph3 HR+/HER2- BC (OVELIA)
A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA) Read Moreabout Ph3 HR+/HER2- BC (OVELIA)
Phase: III
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554) Read Moreabout Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
Phase: III
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784) Read Moreabout Ph3 GDC-9545 ER+ HER2- BC (lidERA)
Phase: III
Ph3 HER2/neu BC (FLAMINGO-01)
A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01) Read Moreabout Ph3 HER2/neu BC (FLAMINGO-01)
Phase: III
Ph1a/1b LY3484356 Abem ER+ HER2-
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA) Read Moreabout Ph1a/1b LY3484356 Abem ER+ HER2-
Phase: I
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY Read Moreabout Ph3 Nira Her2- triple- BC ctDNA (ZEST)
Phase: III
Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC
postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF) Read Moreabout Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC
Phase: III
Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4)
SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001) Read Moreabout Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4)
Phase: III
Ph3 Enob Abem ER+HER2- BC
V2000701:A Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm in Combination with Abemaciclib (Enobosarm Combination Group) compared to Estrogen Blocking Agent (Control Treated Group) for the Second Line Treatment of ER+HER2- Metastatic Breast Cancer in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent plus Palbociclib or Ribociclib (ENABLAR-2) Read Moreabout Ph3 Enob Abem ER+HER2- BC
Phase: III
Ph1b AMG 510 MVASI Combo KRAS CRC
20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M) Read Moreabout Ph1b AMG 510 MVASI Combo KRAS CRC
Phase: I
Ph1b AMG 510 + TNO155 KRAS p.G12C Solids
20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib (AMG 510) in Combination with TNO155 in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol N) Read Moreabout Ph1b AMG 510 + TNO155 KRAS p.G12C Solids
Phase: I
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C) Read Moreabout Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
Phase: I
STAR Ph3 MRTX849 Cetux KRAS G12C CC
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010) Read Moreabout STAR Ph3 MRTX849 Cetux KRAS G12C CC
Phase: III
Ph2 Epidemi Colon Cancer
Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001) Read Moreabout Ph2 Epidemi Colon Cancer
Phase: II/III
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
Ph 3 Pemb v Plat Dbl dMMR Endo Carcinoma
A Phase 3 Randomized Open-label Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (MK-3475-C93/GOG-3064) Read Moreabout Ph 3 Pemb v Plat Dbl dMMR Endo Carcinoma
Phase: III
INCMGA00012 Endo Cancer
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204) Read Moreabout INCMGA00012 Endo Cancer
Phase: II
Ph1a/1b LY3484356 Abem ER+ HER2-
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA) Read Moreabout Ph1a/1b LY3484356 Abem ER+ HER2-
Phase: I
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
Ph3 Upif Rilso Ovarian Cancer
A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049) Read Moreabout Ph3 Upif Rilso Ovarian Cancer
Phase: III
Ph2 AKT Pac vs Ova fall and Peri
An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri
Phase: II
STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01) Read Moreabout STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
Phase: I
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
PH2 Brentux+CHP In Tx Naive PTCL
A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read Moreabout PH2 Brentux+CHP In Tx Naive PTCL
Phase: II
STAR: Zanu in Acala intolerant B-Cell
A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell
Phase: II
Ph1b AMG 510 + TNO155 KRAS p.G12C Solids
20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib (AMG 510) in Combination with TNO155 in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol N) Read Moreabout Ph1b AMG 510 + TNO155 KRAS p.G12C Solids
Phase: I
Ph1b AMG 510 in Combo NSCLC KRAS p.G12C
20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F) Read Moreabout Ph1b AMG 510 in Combo NSCLC KRAS p.G12C
Phase: I
Ph1b AMG510 + Pembro NSCLC KRAS G12C
20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I) Read Moreabout Ph1b AMG510 + Pembro NSCLC KRAS G12C
Phase: I
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C) Read Moreabout Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
Phase: I
Ph1b Sotora NSCLC KRAS p.G12C Brain Met
20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G) Read Moreabout Ph1b Sotora NSCLC KRAS p.G12C Brain Met
Phase: I
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
STAR Ph2 MRTX849 Pembro NSCLC KRAS
A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout STAR Ph2 MRTX849 Pembro NSCLC KRAS
Phase: II
A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
STAR Ph3 Ami Laz EGFR-mut NSCLC
A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002) Read Moreabout STAR Ph3 Ami Laz EGFR-mut NSCLC
Phase: III
STAR PH3 EGFRm stage2/3b NSCLC
A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001) Read Moreabout STAR PH3 EGFRm stage2/3b NSCLC
Phase: III
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC
Phase: III
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
Phase: III
Ph2 Tomivosertib+Anti-PD-L1 NSCLC
A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011) Read Moreabout Ph2 Tomivosertib+Anti-PD-L1 NSCLC
Phase: II
Ph2 Nap r/r NSCLC
NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER Read Moreabout Ph2 Nap r/r NSCLC
Phase: II
STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies Read Moreabout STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
Phase: II
STAR BV in pts w/1L cHL or PTCL
(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read Moreabout STAR BV in pts w/1L cHL or PTCL
Phase: II
PH2 Brentux+CHP In Tx Naive PTCL
A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read Moreabout PH2 Brentux+CHP In Tx Naive PTCL
Phase: II
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
Phase: I
STAR: Zanu in Acala intolerant B-Cell
A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell
Phase: II
Ph2 Lonca-R DLBCL
A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203) Read Moreabout Ph2 Lonca-R DLBCL
Phase: II
Ph2 Epco r/r B-Cell Lymph out pt
A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362) Read Moreabout Ph2 Epco r/r B-Cell Lymph out pt
Phase: II
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: II/III
Ph3 LOXO-305 vs PC of BTK in MCL
A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019) Read Moreabout Ph3 LOXO-305 vs PC of BTK in MCL
Phase: III
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020) Read Moreabout Ph3 LOXO-305 vs. InvChoice in CLL/SLL
Phase: III
Ph2 Sub Mosunetuzumab B-cell malig
AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig
Phase: II
LTFU T-Cells
GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS. Read Moreabout LTFU T-Cells
Phase: II/III
Ph3 Tafa+ Lena R-CHOP B-Cell Lymp
MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Read Moreabout Ph3 Tafa+ Lena R-CHOP B-Cell Lymp
Phase: III
Ph1b/2 XMT-1536 ST NaPi2b
A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048) Read Moreabout Ph1b/2 XMT-1536 ST NaPi2b
Phase: II
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
STAR Ph2 VS-6766 Fak-Inhib LGSOC
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052) Read Moreabout STAR Ph2 VS-6766 Fak-Inhib LGSOC
Phase: II
Ph3 Upif Rilso Ovarian Cancer
A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049) Read Moreabout Ph3 Upif Rilso Ovarian Cancer
Phase: III
Ph2 AKT Pac vs Ova fall and Peri
An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri
Phase: II
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
Ph3 Upif Rilso Ovarian Cancer
A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049) Read Moreabout Ph3 Upif Rilso Ovarian Cancer
Phase: III
Ph2 AKT Pac vs Ova fall and Peri
An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri
Phase: II
Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C
20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H) Read Moreabout Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C
Phase: I
Ph1b AMG 510 + TNO155 KRAS p.G12C Solids
20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib (AMG 510) in Combination with TNO155 in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol N) Read Moreabout Ph1b AMG 510 + TNO155 KRAS p.G12C Solids
Phase: I
Ph1b AMG 510 + Palboc ST KRAS p.G12C
20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J) Read Moreabout Ph1b AMG 510 + Palboc ST KRAS p.G12C
Phase: I
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C) Read Moreabout Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
Phase: I
A Phase 1, Multi-center, Open-label, Single-arm, Dose escalation, First-in-human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 Monotherapy in Patients with Locally Advanced/Metastatic Solid Tumours
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
Phase: I
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007) Read Moreabout STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
Phase: II
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations
Phase: II
STAR Ph2 Seribantumab NRG1 Fusion+ ST
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01) Read Moreabout STAR Ph2 Seribantumab NRG1 Fusion+ ST
Phase: II
PATHFINDER 2 Early Detection Test
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012) Read Moreabout PATHFINDER 2 Early Detection Test
Phase: IV